达格列净在2型糖尿病合并3b-4期慢性肾脏病患者中的效应
该汇总分析纳入11项3期随机对照试验,比较安慰剂(n=69)与达格列净5或10 mg(n=151)在eGFR 12至<45 mL/min/1.73 m2的2型糖尿病患者中102周内的变化。达格列净未显著降低HbA1c,但降低UACR、血压和体重,且10 mg组肾脏相关不良事件更常见。
要点
- 达格列净未显著降低3b-4期CKD患者的HbA1c。
- 达格列净5 mg和10 mg分别降低UACR 47.1%和38.4%。
- 达格列净10 mg组肾脏相关不良事件更常见,主要为无症状血肌酐升高。
核心结论
- 达格列净未降低2型糖尿病合并3b-4期CKD患者的HbA1c,但降低UACR、血压和体重至临床有意义程度。
研究设计与样本
- 汇总分析11项3期随机对照临床试验,eGFR 12至<45 mL/min/1.73 m2的2型糖尿病患者接受安慰剂(n=69)或达格列净5或10 mg(n=151),观察102周。
主要发现
- 达格列净5 mg和10 mg相比安慰剂的HbA1c变化分别为0.03%(95%CI -0.3-0.3)和0.03%(95%CI -0.2-0.3)。
- 达格列净5 mg和10 mg相比安慰剂分别降低UACR 47.1%(95%CI -64.8至-20.6)和38.4%(95%CI -57.6至-10.3)。
- 达格列净5 mg和10 mg相比安慰剂还降低血压和体重。
- 随访结束时组间eGFR无差异;安慰剂组eGFR在前4周升高,达格列净组无变化。
- 达格列净10 mg组肾脏相关不良事件更频繁,主要为无症状性血清肌酐升高。
关键数值与推荐
- UACR效应在基线UACR≥30 mg/g的亚组(n=136)中评估。
临床怎么用
- 在2型糖尿病合并3b-4期CKD患者中,达格列净虽不改善血糖,但可降低白蛋白尿、血压和体重,需关注血肌酐变化。
局限性
- 该分析为汇总分析,样本量有限,需大型结局试验确认长期安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this drug have not been properly defined in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (CKD). METHODS: In a pooled analysis of 11 phase 3 randomized controlled clinical trials, we determined least square mean changes in HbA1c, body weight, BP, estimated glomerular filtration rate (eGFR) and UACR over 102 weeks in patients with type 2 diabetes and an eGFR between 12 to less than 45 mL/min/1.73 m2 receiving placebo (n = 69) or dapagliflozin 5 or 10 mg (n = 151). Effects on UACR were determined in a subgroup of patients with baseline UACR ≥30 mg/g (n = 136). RESULTS: Placebo-corrected changes in HbA1c with dapagliflozin 5 and 10 mg were 0.03% [95% confidence interval (CI) -0.3-0.3] and 0.03% (95% CI -0.2-0.3) during the overall 102-week period. Dapagliflozin 5 and 10 mg compared with placebo reduced UACR by - 47.1% (95% CI -64.8 to - 20.6) and -38.4% (95% CI -57.6 to - 10.3), respectively. Additionally, dapagliflozin 5 and 10 mg compared with placebo reduced BP and body weight. eGFR increased with placebo during the first 4 weeks but did not change with dapagliflozin. There were no between-group differences in eGFR at the end of follow-up. Adverse events associated with renal function occurred more frequently in the dapagliflozin 10-mg group. These events were mainly asymptomatic increases in serum creatinine. CONCLUSIONS: Dapagliflozin did not decrease HbA1c in patients with type 2 diabetes and Stages 3b-4 CKD, but decreased UACR, BP and body weight to a clinically meaningful extent. These results support a large outcome trial in this population to confirm long-term safety and efficacy in reducing adverse clinical endpoints.
引用
- Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018. PMID: 29370424. doi:10.1093/ndt/gfx350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。